EMA Withdrawn: Portrazza (necitumumab) — Eli Lilly Nederland B.V.

View source ↗

Summary

Portrazza (necitumumab) has been withdrawn by its marketing authorization holder in the EMA framework.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Portrazza (necitumumab)

Snippet

Status: Withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Eli Lilly Nederland B.V.. Decision date: 18/02/2021